CLINICAL_TRIALS
trial_result
· 2006-12-04
Clinical Trial Update: Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients [Phase 3]
Summary
A Phase 3 study evaluating eculizumab in transfusion-dependent paroxysmal nocturnal hemoglobinuria has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hemoglobinuria, Paroxysmal | Phase 3 | Status: COMPLETED